[go: up one dir, main page]

AR061015A1 - Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto - Google Patents

Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto

Info

Publication number
AR061015A1
AR061015A1 ARP070102147A ARP070102147A AR061015A1 AR 061015 A1 AR061015 A1 AR 061015A1 AR P070102147 A ARP070102147 A AR P070102147A AR P070102147 A ARP070102147 A AR P070102147A AR 061015 A1 AR061015 A1 AR 061015A1
Authority
AR
Argentina
Prior art keywords
receiver
optionally substituted
composition
compound
group
Prior art date
Application number
ARP070102147A
Other languages
English (en)
Inventor
Derek Cecil Cole
Magda Asselin
Gmbh Co Kg Stockhausen
Ji-In Kim
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR061015A1 publication Critical patent/AR061015A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1), caracterizado porque X es CO, CH2 o SOm; Y es NR6, NR6CO, O o SOp; m y p son cada uno individualmente 0 o un entero de 1 o 2; R1 y R2 son cada uno independientemente H o un grupo alquilo opcionalmente sustituido o R1 y R2 pueden ser tomados juntos con el átomo al cual ellos están unidos para formar un anillo de 4 a 7 miembros opcionalmente sustituido que contiene uno o dos heteroátomos adicionales seleccionados de N, O o S; R3 es NR7R8 o un grupo arilo o heteroarilo cada grupo opcionalmente sustituido con la condicion de que cuando Y es NR6, O o SOp entonces R3 debe ser un grupo arilo o heteroarilo cada grupo opcionalmente sustituido; R4 y R5 son cada uno independientemente H, halogeno, OR9 o un grupo alquilo, alquenilo, alquinilo, cicloalquilo, cicloheteroalquilo, arilo, o heteroarilo cada uno opcionalmente sustituido; R6 y R9 son cada uno independientemente H o un grupo alquilo opcionalmente sustituido; y R7 y R8 son tomados juntos con el átomo al cual ellos están unidos para formar un sistema de anillo de 9- a 11- miembros opcionalmente sustituido bicíclico o tricíclico fusionado que contiene opcionalmente uno a tres heteroátomos adicionales seleccionados de N, O o S; o un estereoisomero de éstos o una sal farmacéuticamente aceptable de éstos.
ARP070102147A 2006-05-19 2007-05-18 Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto AR061015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80190506P 2006-05-19 2006-05-19

Publications (1)

Publication Number Publication Date
AR061015A1 true AR061015A1 (es) 2008-07-30

Family

ID=38616614

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102147A AR061015A1 (es) 2006-05-19 2007-05-18 Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto

Country Status (12)

Country Link
US (1) US7842715B2 (es)
EP (1) EP2027086B1 (es)
JP (1) JP2009537542A (es)
CN (1) CN101432261A (es)
AR (1) AR061015A1 (es)
AT (1) ATE533744T1 (es)
AU (1) AU2007254232A1 (es)
CA (1) CA2649913A1 (es)
MX (1) MX2008014743A (es)
PE (1) PE20080371A1 (es)
TW (1) TW200811165A (es)
WO (1) WO2007136668A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007227681A1 (en) * 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2009143153A1 (en) * 2008-05-23 2009-11-26 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine h3 receptor
TW201024307A (en) * 2008-09-10 2010-07-01 Kalypsys Inc Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
US20130245064A1 (en) * 2010-11-01 2013-09-19 Shaheen Ahmed Novel neurotrypsin inhibitors
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102784146A (zh) * 2011-05-19 2012-11-21 复旦大学 N-苯基喹唑啉-4-胺类衍生物的药用用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
DK111387A (da) 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
CA2136999C (en) 1993-04-07 2004-05-11 Takafumi Fujioka Peripheral vasodilating agent containing piperidine derivative as active ingredient
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5747485A (en) * 1995-04-13 1998-05-05 Merck & Co., Inc. Substituted azetidiones as anti-inflammatory and antidegenerative agents
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
AU7270798A (en) 1997-05-01 1998-11-24 Eli Lilly And Company Antithrombotic agents
AU9206798A (en) 1997-08-28 1999-03-16 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
CN100418951C (zh) * 1997-11-18 2008-09-17 帝人医药株式会社 环胺衍生物及其作为药物的用途
CA2338209A1 (en) 1998-07-20 2000-02-03 Merck Patent Gesellschaft Mit Beschraenkter Haftung Biphenyl derivatives
AU2180500A (en) 1998-12-15 2000-07-03 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
WO2001042224A1 (en) * 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
AU2001247906A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted indoles and indazoles
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AU2002357728A1 (en) 2001-11-09 2003-05-19 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
ATE447404T1 (de) * 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
CA2481229C (en) 2002-04-08 2010-09-21 Merck & Co., Inc. Substituted pyrazine inhibitors of akt
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
EP1569905A2 (en) 2002-12-06 2005-09-07 Eli Lilly And Company Inhibitors of monoamine uptake
ATE489388T1 (de) 2003-03-14 2010-12-15 Medigene Ltd Immunmodulierende heterocyclische verbindungen
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
JP4467616B2 (ja) * 2004-05-14 2010-05-26 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
EP1786790B1 (en) 2004-07-26 2009-06-03 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
JP4942654B2 (ja) 2004-08-23 2012-05-30 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体薬剤、製剤及び治療的使用
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
MX2007008843A (es) * 2005-01-21 2007-08-22 Schering Corp Derivados de imidazol y bencimidazol utiles como antagonistas de histamina h3.
US7605272B2 (en) 2005-01-27 2009-10-20 Kyowa Hakko Kirin Co., Ltd. IGF-1R inhibitor
WO2006113140A2 (en) * 2005-04-15 2006-10-26 Elan Pharmaceuticals, Inc. Novel compounds useful for bradykinin b1 receptor antagonism
AU2007227681A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
CA2646585A1 (en) 2006-03-20 2007-09-27 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
US20070238718A1 (en) 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Also Published As

Publication number Publication date
EP2027086B1 (en) 2011-11-16
WO2007136668A3 (en) 2008-01-24
AU2007254232A1 (en) 2007-11-29
CN101432261A (zh) 2009-05-13
JP2009537542A (ja) 2009-10-29
CA2649913A1 (en) 2007-11-29
US7842715B2 (en) 2010-11-30
PE20080371A1 (es) 2008-04-09
ATE533744T1 (de) 2011-12-15
MX2008014743A (es) 2008-12-01
EP2027086A2 (en) 2009-02-25
TW200811165A (en) 2008-03-01
US20070270440A1 (en) 2007-11-22
WO2007136668A2 (en) 2007-11-29
WO2007136668A9 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
AR061015A1 (es) Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto
AR059905A1 (es) Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto
AR068423A1 (es) Compuesto, composicion farmaceutica y uso del compuesto en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina-3 (h3) y proceso para la preparacion del compuesto
UY28578A1 (es) Derivados de amida
AR078786A1 (es) Derivados de la cromenona
EA201000946A1 (ru) Бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
AR083831A1 (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
AR063147A1 (es) Compuestos heterociclicos nitrogenados inhibidores de receptores de histamina h3, metodo de preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos del sistema nervioso central.
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
AR066111A1 (es) Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto
SV2017005384A (es) Compuestos aminopirimidinilo
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR046964A1 (es) Heterociclos azabiciclicos como moduladores de receptor canabinoide, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion.
NZ779654A (en) Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR078408A1 (es) Derivados de indol como moduladores de los crac
AR087309A1 (es) Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
BR112012028992A2 (pt) 1 - [(4-hidroxipiredina-4-il)metil]piridina-2 (1h) -ona, método de preparação e utilização dos mesmos
CR20190261A (es) Inhibidores de la tirosina quinasa de bruton
AR100530A1 (es) Compuestos antihelmínticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure